Abstract |
Here we found that serum levels of thioredoxin were increased in patients with hepatocellular carcinoma (HCC). The optimum diagnostic cutoff for thioredoxin was 20.5 ng/mL (area under curve [AUC] 0.946 [95% CI 0.923-0.969] in the training cohort; 0.941 [0.918-0.963] in the validation cohort). High serum concentrations of thioredoxin differentiated HCC from chronic liver diseases and cirrhosis (0.901 [0.875-0.923] in the training cohort; 0.906 [0.870-0.925] in the validation cohort). Furthermore, a higher proportion of patients with very early HCC had positive results for thioredoxin than for alpha-Fetoprotein (AFP) (73.7% VS.31.6%; P < 0.0001). Among AFP-negative patients with very early HCC, 18 (69.2%) of 26 had positive thioredoxin results. Our results indicate that serum thioredoxin complements measurement of AFP in the diagnosis of HCC, especially in very early disease. Combined model ( thioredoxin and AFP) showed a significantly greater discriminatory ability as compared with those markers alone.
|
Authors | Jun Li, Zhang-Jun Cheng, Yang Liu, Zhen-Lin Yan, Kui Wang, Dong Wu, Xu-Ying Wan, Yong Xia, Wan Yee Lau, Meng-Chao Wu, Feng Shen |
Journal | Oncotarget
(Oncotarget)
Vol. 6
Issue 11
Pg. 9551-63
(Apr 20 2015)
ISSN: 1949-2553 [Electronic] United States |
PMID | 25871387
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- AFP protein, human
- Biomarkers, Tumor
- Neoplasm Proteins
- alpha-Fetoproteins
- Thioredoxins
|
Topics |
- Area Under Curve
- Biomarkers, Tumor
(blood)
- Carcinoma, Hepatocellular
(diagnosis, epidemiology)
- China
(epidemiology)
- Diagnosis, Differential
- Disease Progression
- Early Diagnosis
- Female
- Humans
- Liver Cirrhosis
(blood)
- Liver Diseases
(blood)
- Liver Neoplasms
(diagnosis, epidemiology)
- Male
- Middle Aged
- Models, Biological
- Neoplasm Proteins
(blood)
- ROC Curve
- Sensitivity and Specificity
- Thioredoxins
(blood)
- Tumor Burden
- alpha-Fetoproteins
(analysis)
|